Abstract
DNA hypermethylation has been widely observed in temporal lobe epilepsy (TLE). While NR4A1 knockdown has been reported to alleviate seizure severity in mouse models, the underlying methylation-imaging pathway modulated by aberrant NR4A1 methylation levels remains to be clarified in human patients. This study utilizes multi-site canonical correlation analysis with reference (MCCAR) to guide the fusion of three MRI features—functional connectivity (FC), fractional anisotropy (FA), and gray matter volume (GMV)—using blood-based NR4A1 methylation levels as a prior for 56 TLE patients and 65 healthy controls. Post-hoc correlations were evaluated between the identified NR4A1-associated brain components and clinical metrics.
Introduction
Temporal Lobe Epilepsy (TLE) is the most prevalent form of focal epilepsy, often characterized by resistance to standard pharmacological treatments. While genetic factors contribute to TLE risk, they account for only approximately 32% of the variance, highlighting the potential role of epigenetic mechanisms—how environmental factors change gene expression without altering the DNA sequence. DNA hypermethylation of the NR4A1 gene is a promising candidate, as its modulation has shown therapeutic potential in animal models. However, the link between peripheral molecular markers and macroscopic brain network disruptions in humans has remained elusive. This study aims to determine if NR4A1 methylation levels in the blood can serve as a biological "guide" to identify specific patterns of brain impairment in TLE patients.
Methodology: Multimodal Fusion via MCCAR
The study recruited 121 participants, including 56 TLE patients and 65 healthy controls. The TLE group was further divided into right-sided (n=27) and left-sided (n=26) subsets. Researchers employed the Multi-site Canonical Correlation Analysis with Reference (MCCAR) technique to integrate multimodal neuroimaging data guided by NR4A1 methylation levels. Unlike unsupervised methods, MCCAR uses a biological anchor to isolate specific brain networks most sensitive to the epigenetic marker across three modalities: Functional Connectivity (fMRI), Fractional Anisotropy (dMRI), and Gray Matter Volume (sMRI).
Key Results
The Blood-Brain Epigenetic Pathway
The analysis revealed significantly higher NR4A1 methylation levels in TLE patients compared to controls (0.34 vs 0.28, $p < 10^{-6}$). These elevated levels were quantitatively linked to a specific pattern of multimodal brain impairment:
- Functional Connectivity (FC): Impaired strength in temporal-cerebellar and occipital-cerebellar circuits.
- Structural Integrity (FA): Lower fractional anisotropy (decreased white matter integrity) in the cingulum and hippocampus.
- Morphometry (GMV): Reduced gray matter volume in the thalamus, putamen, temporal pole, and cerebellum.
Clinical and Cognitive Correlations
These neuroimaging "loadings" were significantly correlated with clinical outcomes. Higher methylation and associated brain damage predicted earlier disease onset and poorer cognitive performance, as measured by the Minimum Mental State Examination (MMSE) and executive function accuracy (Hayling Sentence Complete Test). Notably, patients with Right TLE exhibited more pronounced brain impairment and cognitive deficits compared to those with Left TLE, particularly showing more reduced GMV in the thalamus.
Discussion and Clinical Implications
These findings establish a potential imaging-methylation pathway where peripheral NR4A1 methylation levels reflect central nervous system disruptions. The involvement of the thalamus and putamen as critical nodes suggests that this epigenetic marker tracks the integrity of networks involved in seizure propagation. The lateralization effects observed underscore the complexity of TLE and the potential for blood-based epigenetic markers to serve as accessible biomarkers for brain health and disease progression.
Limitations and Future Work
The cross-sectional nature of the study precludes definitive causal conclusions regarding whether methylation causes brain changes or vice versa. Future research should focus on longitudinal assessments and broader epigenetic landscapes beyond a single gene to fully map the molecular drivers of TLE. Additionally, larger multi-center studies are needed to validate these imaging-methylation pathways for clinical diagnostics.
Summary updated